Mutations causing syndromic autism define an axis of synaptic pathophysiology

Nature

Volumn 480, Issue 7375, 2011, Pages 63-68

  Auerbach, Benjamin D ^a   Osterweil, Emily K ^a   Bear, Mark F ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIHYDROXYPHENYLGLYCINE; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR 5;

BIOASSAY; BIOCHEMICAL COMPOSITION; COGNITION; DEVELOPMENTAL BIOLOGY; DISABILITY; DISEASE PREVALENCE; MUTATION; NERVOUS SYSTEM DISORDER; NEUROLOGY; PATHOLOGY; RODENT;

ANIMAL EXPERIMENT; ARTICLE; AUTISM; BREEDING; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HIPPOCAMPUS; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANIMALS; AUTISTIC DISORDER; DISEASE MODELS, ANIMAL; ELECTRICAL SYNAPSES; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MUTATION; RECEPTORS, METABOTROPIC GLUTAMATE; SYNDROME; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 82555196668     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10658     Document Type: Article

References (55)

1. Newschaffer, C.J.et al. The epidemiologyof autism spectrum disorders.Annu. Rev. Public Health 28, 235-258 (2007).
2. Krueger, D. D. & Bear, M. F. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411-429 (2011).
3. Kelleher, R. J. III & Bear, M. F. The autistic neuron: troubled translation? Cell 135, 401-406 (2008).
4. 1/2 mouse model of tuberous sclerosis. Nature Med. 14, 843-848 (2008).
5. Meikle, L.etal. Responseofaneuronal modeloftuberous sclerosistomammalian targetofrapamycin (mTOR) inhibitors: effectsonmTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422-5432 (2008).
6. Onda, H.etal. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cell. Neurosci. 21, 561-574 (2002). (Pubitemid 36062714)
7. Ehninger, D., de Vries, P. J. & Silva, A. J. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J. Intellect. Disabil. Res. 53, 838-851 (2009).
8. Carbonara, C.etal. 9q34 lossofheterozygosityinatuberous sclerosis astrocytoma suggestsa growth suppressor-like activity also for the TSC1 gene. Hum. Mol. Genet. 3, 1829-1832 (1994). (Pubitemid 24310479)
9. Green, A. J., Smith, M. & Yates, J. R. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nature Genet. 6, 193-196 (1994). (Pubitemid 24188602)
10. de Vries, P. J. & Howe, C. J. The tuberous sclerosis complex proteins-a GRIPP on cognition and neurodevelopment. Trends Mol. Med. 13, 319-326 (2007). (Pubitemid 47126986)
11. 1/2 mice in the absence of cerebral lesions and seizures. Ann. Neurol. 62, 648-655 (2007).
12. Cheadle, J. P., Reeve, M. P., Sampson, J. R. & Kwiatkowski, D. J. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107, 97-114 (2000).
13. 1/2 mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687-695 (1999). (Pubitemid 29536354)
14. Nie, D.etal. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nature Neurosci. 13, 163-172 (2010).
15. Young, D. M., Schenk, A. K., Yang, S. B., Jan, Y. N. & Jan, L. Y. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism. Proc. Natl Acad. Sci. USA 107, 11074-11079 (2010).
16. Hoeffer, C. A. & Klann, E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67-75 (2010).
17. Sharma, A. et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694-702 (2010).
18. Huber, K. M., Kayser, M. S. & Bear, M. F. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 288, 1254-1257 (2000).
19. Huber, K. M., Roder, J.C.& Bear, M. F.Chemical inductionof mGluR5-and protein synthesis-dependent long-term depression in hippocampal area CA1. J. Neurophysiol. 86, 321-325 (2001). (Pubitemid 32623237)
20. Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl Acad. Sci. USA 99, 7746-7750 (2002). (Pubitemid 34568762)
21. Bear, M. F., Huber, K. M. & Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377 (2004). (Pubitemid 38829251)
22. Gallagher, S. M., Daly, C. A., Bear, M.F.& Huber, K. M. Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. J. Neurosci. 24, 4859-4864 (2004). (Pubitemid 38668210)
23. Osterweil, E.K., Krueger, D.D., Reinhold, K.& Bear, M.F.Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 15616-15627 (2010).
24. Fitzjohn, S. M. et al. A characterisation of long-term depression induced by metabotropic glutamate receptor activation in the rat hippocampus in vitro. J. Physiol. 537, 421-430 (2001). (Pubitemid 33130499)
25. Nosyreva, E. D. & Huber, K. M. Developmental switch in synaptic mechanisms of hippocampalmetabotropic glutamatereceptor-dependentlong- termdepression. J. Neurosci. 25, 2992-3001 (2005). (Pubitemid 40389257)
26. Mockett, B. G. et al. Calcium/calmodulin-dependent protein kinase II mediates group I metabotropic glutamate receptor-dependent protein synthesis and long-term depression in rat hippocampus. J. Neurosci. 31, 7380-7391 (2011).
27. Luscher, C. & Huber, K. M. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65, 445-459 (2010).
28. Snyder, E. M. et al. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nature Neurosci. 4, 1079-1085 (2001). (Pubitemid 34116552)
29. Waung, M. W., Pfeiffer, B. E., Nosyreva, E. D., Ronesi, J. A. & Huber, K. M. Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron 59, 84-97 (2008). (Pubitemid 351905854)
30. Park, S. et al. Elongation factor 2 and fragile X mental retardation protein control the dynamictranslationofArc/Arg3.1essential formGluR-LTD. Neuron59, 70-83 (2008). (Pubitemid 351905855)
31. Dolen, G. et al. Correction of fragile X syndrome in mice. Neuron 56, 955-962 (2007). (Pubitemid 350251119)
32. Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41-54 (2009).
33. Kinney, G. G. et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313, 199-206 (2005). (Pubitemid 40411343)
34. Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J. & Silva, A. J. The dorsal hippocampus is essential for context discrimination but not for contextual conditioning. Behav. Neurosci. 112, 863-874 (1998). (Pubitemid 28397368)
35. Lu, Y. M. et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17, 5196-5205 (1997).
36. Stiedl, O., Palve, M., Radulovic, J., Birkenfeld, K.& Spiess, J. Differential impairment of auditory and contextual fear conditioning by protein synthesis inhibition in C57BL/6N mice. Behav. Neurosci. 113, 496-506 (1999). (Pubitemid 29340062)
37. Bassell, G. J. & Warren, S. T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214 (2008).
38. Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261 (2011).
39. Dolen, G., Carpenter, R.L., Ocain, T.D.&Bear, M.F.Mechanism-based approaches to treating fragile X. Pharmacol. Ther. 127, 78-93 (2010).
40. Narayanan, U. et al. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J. Biol. Chem. 283, 18478-18482 (2008).
41. Fombonne, E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J. Autism Dev. Disord. 33, 365-382 (2003). (Pubitemid 37127933)
42. Ramocki, M.B.& Zoghbi, H. Y.Failureofneuronal homeostasis results incommon neuropsychiatric phenotypes. Nature 455, 912-918 (2008).
43. Krueger, D.D., Osterweil, E.K.& Bear, M. F. Activationof mGluR5 induces rapid and long-lasting protein kinase D phosphorylation in hippocampal neurons. J. Mol. Neurosci. 42, 1-8 (2010).
44. Zhu, X. et al. Genes Dev. 20, 2739-2753 (2006).
45. Kita, A. et al. Mol. Endocrinol. 21, 1458-1466 (2007).
46. Ericson, J., Norlin, S., Jessell, T. M. & Edlund, T. Development 125, 1005-1015 (1998).
47. Treier, M. et al. Genes Dev. 12, 1691-1704 (1998).
48. Davis, S. W., Mortensen, A. H. & Camper, S. A. Dev. Biol. 352, 215-227 (2011).
49. Lepore, D. A. et al. Stem Cells 25, 1730-1736 (2007).
50. Murry, C. E. & Keller, G. Cell 132, 661-680 (2008).
51. Lafont, C. et al. Proc. Natl Acad. Sci. USA 107, 4465-4470 (2010).
52. Schaeffer, M. et al. Endocrinology http://dx.doi. org/10.1210/en.2011- 1430 (2011).
53. Griffith, L. G. & Swartz, M. A. Nature Rev. Mol. Cell Biol. 7, 211-224 (2006).
54. Orlando, G. et al. Transpl. Int. 24, 223-232 (2011).
55. Green, M. D. et al. Nature Biotechnol. 29, 267-272 (2011).